One hot dry period, three generations pay: daughter and granddaughter give less milk.
It's epigenetic. The fix: rumen-protected methionine in transition.
In MEA it's not a summer story.
Cooling protects today. Nutrition protects tomorrow.
#HeatStress#SmartamineM#Adisseo
Without exception, every high performer I’ve studied credits a host of supporters for success. Research has found that a willingness to ask for help is crucial to achievement.
I Study Successful People. They Have One Habit in Common. https://t.co/rakqq3bXev via @NYTOpinion
Dr. Scott Berry explains that a solution to the problem of “I’ll know it when I see it” for funding is to show them examples of what success looks like before the trial starts.
We address ambiguity by collaborating with stakeholders—presenting simulated datasets, effect sizes, and data summaries to help clarify and define actionable decision thresholds.
Through this iterative process, we help transform vague notions into concrete, data-driven criteria that support confident trial advancement.
Learn more on the latest episode of "In the Interim..." https://t.co/pjcTAObKh7
Episode 38 of "In the Interim…" features guest host Cooper Berry interviewing fellow family members Dr. Donald Berry, Dr. Scott Berry, Dr. Lindsay Berry, and Dr. Nick Berry for an in-depth discussion on the trajectory of Bayesian statistics in clinical trials from three generations of Bayesian statisticians working in clinical trials.
From bandit problems in the 1970s to today's adaptive platform trials, this conversation traces how Bayesian methods evolved from mathematical theory to essential clinical trial methodology. Don reflects on 50+ years pioneering Bayesian approaches despite early resistance. Scott discusses how Markov Chain Monte Carlo (MCMC) methods changed everything in the 1990s. Lindsay and Nick explore where we're headed, from AI integration to decision theory.
A key insight from the conversation is that Bayesian thinking isn't just for statisticians. It's how humans naturally learn and update beliefs based on new evidence. The question isn't whether Bayesian methods will dominate clinical trials, it's when.
Listen now: https://t.co/x5lXEvapco
“This is a Bayesian study, please remove that frequentist analysis from the paper. So then I knew that things were possible.”
Prof. Frank Harrell describes a watershed moment in Bayesian trial design when a Lancet reviewer’s directive marked a clear acceptance of pure Bayesian methodology in clinical research publishing.
Hear more on "In the Interim…": https://t.co/5LM9rwEBBr
🔔 Price Benchmarks FCA Europe – Week 36
📌 Takeaway for mid-size factories:
✅ Most amino acids & vitamins are cheaper than Q2 → good moment to negotiate contracts.
⚠️ Watch Vitamin B5, C Phosphate, and D3 → short-term upward signals.
Overall trend: Downward market
#FCAEurope
Повышение цен на продовольствие оказывает разрушительное воздействие на самых бедных и уязвимых слоев населения.
У фермеров сейчас есть беспрецедентная возможность повлиять на сложившуюся ситуацию в мире - включая в корма эмульгатор #ЭнерджиПлюс. Больше корма - меньше денег.